Anti-Insulin-Like Growth Factor Binding Protein 5 (IGFBP5, IBP5, IBP-5)

Insulin-like growth factor binding protein 5 (IGFBP5) is one of a family of proteins that bind IGF and modulate its biological activity. IGFBP-5 is the predominant IGFBP found in bone extracts. The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF. IGFBP5 is the most conserved and is developmentally up-regulated in key lineages and pathologies, in vitro studies suggest that IGFBP-5 functions independently of IGF interaction. Genetic ablation of individual IGFBP's has yielded limited phenotypes because of substantial compensation by remaining family members. Applications: Suitable for use in Direct ELISA, Immunohistochemistry and Western Blot. Other applications not tested. Recommended Dilutions: Immunohistochemistry: 5-15ug/ml using immersion fixed paraffin-embedded sections of human placenta, Western Blot: 0.1ug/ml, Optimal dilutions to be determined by the researcher. Storage and Stability: Lyophilized powder may be stored at -20°C. Stable for 12 months after receipt at -20°C. Reconstitute with sterile PBS. Aliquot to avoid repeated freezing and thawing. Store at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.